Kodiak Sciences says Zenkuda meets primary endpoint in Phase 3 DAYBREAK wet AMD trial
Bitget2026/09/28 10:31- Kodiak Sciences reported pivotal Phase 3 DAYBREAK trial success in wet age-related macular degeneration for Zenkuda and tabirafusp-ted.
- Both treatments matched aflibercept on vision outcomes at one year, supporting a potential path toward first-line use.
- Zenkuda showed rapid disease control with longer dosing intervals for many patients, strengthening its commercial positioning versus standard anti-VEGF therapy.
- The company plans a multi-indication Zenkuda BLA submission in 4Q2026, anchored by five positive Phase 3 studies.
- Detailed DAYBREAK results will be presented at a company Webex on Sept. 28, 2026.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Synopsys (SNPS.US) partners with OpenAI to develop AI models for chip design, revenue-sharing model drives stock price up by 7%
On Wednesday, chip design software provider Synopsys (SNPS.US) announced that it has reached a partnership agreement with OpenAI. Both parties will jointly develop AI models for the chip business and share related revenues.
BoJ Summary of Opinions: Member says appropriate to keep raising rates in line with economy, price
Rio Tinto secures Bell Bay aluminum smelter operations till 2031
The British Pound rallies on a UK growth upgrade and gives more than half back
Crypto prices
More
